Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer
https://doi.org/10.17650/1994-4098-2013-0-1-2-17-22
Abstract
Assessment of quality of life is an important, valid, informative, and cost-effective procedure for evaluating the efficiency of treatment in patients with breast cancer metastasizing to the bone, receiving therapy with bone-modifying agents, including targeted therapy with denosumab. The administration of denosumab significantly improves quality of life in patients with breast cancer metastasizing to the bone, by maintaining their general status, reducing the intensity of pain syndrome, and prevents osseous complications: pathological fractures, spinal cord compression, hypercalcemia, as well as the need for radiotherapy or surgery for bone metastases.
About the Authors
T. Yu. Semiglazova
N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
V. V. Semiglazov
Acad. I.P. Pavlov Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
L. V. Filatova
N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
P. V. Krivorotko
N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
V. V. Kolarkova
N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
V. F. Semiglazov
N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
References
1. Мерабишвили В.М. Рак молочной железы: заболеваемость, смертность, выживаемость (популяционное исследование). Вопр онкол 2011;57(5):609–15.
2. Fisher B., Osborn K., Margolese R. et al. Neoplasms of the breast. In: Cancer medicine. 3rd ed. Ed. by J. Holland et al. 1993. Рp. 1706–74. 3. Theoleyre S., Wittrant Y., Tat S.K. et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15(6):457–75.
3. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29(2):155–92.
4. Wright H.L., McCarthy H.S., Middleton J., Marshall M.J. RANK, RANKL and osteoprotegerinin bone biology and disease. Curr Rev Musculoskelet Med 2009;2(1):56–64.
5. Body J.J., Greipp P., Coleman R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer
6. ;97(3 Suppl):887–92.
7. Stopeck A.T., Lipton A., Body J.J. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132–9.
8. Levren G., Sadik M., Gjertsson P. et al. Relation between pain and skeletal metastasis in patients with prostate or breast cancer. Clin Physiol Funct Imaging 2011;31(3):193–5.
9. Pecherstorfer M., Jilch R., Sauty A. et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate in circulating lymphocyte subpopulations. J Bone Min Res 2000;15(1):147–54.
10. Clare C., Royle D., Saharia K. et al. Painful bone metastases: a prospective observational cohort study. Palliat Med 2005;19(7):521–5.
11. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Assessment of fracture risk. Eur J Radiol 2009;71(3):392–7.
12. Weinfurt K.P., Li Y., Castel L.D. et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16(4):579–84.
13. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 2004;9 Suppl 4:14–27.
14. Costa L., Badia X., Chow E. et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16(8):879–89.
15. Weinfurt K.P., Castel L.D., Li Y. et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42(2):164–75.
16. Pockett R.D., Castellano D., McEwan P.
17. et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19(6):755–60.
18. Coward D.D., Wilkie D.J. Metastatic bone pain. Meanings associated with self-report and self-management decision making. Cancer Nurs 2000;23(2):101–8.
19. Ионова Т.И., Новик А.А., Сухонос Ю.А. Понятие качества жизни больных онкологического профиля. Онкология 2000;2(1–2):25–8.
20. Aaronson N.K., Cull A., Kaasa S., Sprangers M. The European Organisation for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 1994;23:75–96.
21. Wardley A., Davidson N., Barrett-Lee P. et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92(10):1869–76.
22. Body J.J., Diel I.J., Bell R. et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111(3):306–12.
23. Martin M., Bell R., Bourgeois H. et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012;18(17):4841–9.
24. Diel I.J., Bergner R., Grötz K.A. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5(10):475–82.
25. Perazella M.A., Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int 2008;74(11):1385–93.
26. Tabrizi M.A., Tseng C.M., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11(1–2):81–8.
27. King A.E., Umland E.M. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28(5):667–77.
28. Cavanna L., Bertè R., Arcari A. et al. Osteonecrosis of the jaw. A newly emerging site- specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 2007;18(5):417–22.
29. Marx R.E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567–75.
30. Saad F., Brown J.E., C. Van Poznak С. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23(5):1341–47.
31. Harris K., Chow E., Zhang L. et al. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 2009;45(14):2510–8.
Review
For citations:
Semiglazova T.Yu., Semiglazov V.V., Filatova L.V., Krivorotko P.V., Kolarkova V.V., Semiglazov V.F. Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer. Tumors of female reproductive system. 2013;(1-2):17-22. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-1-2-17-22
Views:
528
Email this article 